Curated News
By: NewsRamp Editorial Staff
March 04, 2026
HeartBeam Partners with ClearCardio to Bring Home ECG Monitoring to Preventive Care
TLDR
- HeartBeam gains a strategic advantage through its first commercial partnership with ClearCardio, securing investment and expanding into preventive cardiology networks.
- HeartBeam's cable-free 3D ECG system synthesizes signals into clinical-grade 12-lead ECGs for home use, integrated via a subscription-based rollout with ClearCardio.
- This partnership enables accessible at-home cardiac monitoring, potentially improving early detection and preventive care for thousands of patients.
- HeartBeam's FDA-cleared technology transforms portable devices into 3D ECG tools, using AI to deliver actionable heart intelligence outside medical facilities.
Impact - Why it Matters
This partnership represents a significant advancement in making cardiac care more accessible and preventive. For patients, it means the ability to capture clinical-grade ECG readings from home, potentially catching arrhythmias and other cardiac issues earlier without frequent clinic visits. This could lead to earlier interventions, better management of chronic conditions, and reduced healthcare costs by preventing more serious cardiac events. For the healthcare system, it demonstrates how technology can bridge gaps in remote monitoring and preventive care, especially valuable for aging populations and those in underserved areas. The investment and commercial rollout signal growing market validation for portable cardiac diagnostics, which could accelerate adoption across other healthcare providers and insurance models.
Summary
HeartBeam (NASDAQ: BEAT), a pioneering medical technology company, has announced a landmark commercial partnership with ClearCardio™, a preventive cardiology practice serving thousands of patients. This strategic alliance marks ClearCardio as HeartBeam's first commercial customer, with plans for a financial investment that underscores their shared vision for transforming cardiac care. The partnership will integrate HeartBeam's groundbreaking synthesized 12-lead ECG technology into ClearCardio's comprehensive heart health screening and personalized prevention programs. This integration enables patients to capture clinical-grade ECG readings from the comfort of their homes using HeartBeam's patented cable-free 3D ECG system, specifically for arrhythmia assessment. The agreement, structured as a Letter of Intent, outlines subscription-based commercial terms and a collaborative deployment plan, supporting HeartBeam's broader growth strategy into concierge care and preventive cardiology networks.
HeartBeam's innovative platform represents a significant leap forward in cardiac monitoring technology. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is designed for portable use wherever the patient is located. With over 20 issued patents, HeartBeam's system allows physicians to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially redefining cardiac health management. The company's continued development includes a 12-lead ECG patch monitor and advancement of AI-driven cardiac care initiatives, positioning it at the forefront of remote patient monitoring.
The announcement was distributed through the InvestorBrandNetwork's specialized communications platform, AINewsWire, which focuses on artificial intelligence advancements and provides comprehensive corporate communications solutions. This platform ensures broad distribution through wire solutions, article syndication to 5,000+ outlets, enhanced press release features, and social media distribution to millions of followers. The full press release detailing this partnership is available for review, providing investors and stakeholders with complete information about this significant development in the medical technology sector. This partnership between HeartBeam and ClearCardio represents a concrete step toward making advanced cardiac diagnostics more accessible and integrated into preventive healthcare models.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Partners with ClearCardio to Bring Home ECG Monitoring to Preventive Care
